Assessment of GORE® EXCLUDER® IBE Plus Stent Graft Performance in Patients Undergoing Endovascular Iliac Revascularization
NCT ID: NCT07304102
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
100 participants
INTERVENTIONAL
2026-09-30
2032-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main questions it aims to answer are:
Does the IBE Plus Stent Graft provide clinical benefit and maintain safety? Does the device maintain effectiveness?
Researchers will evaluate two parallel study arms:
* Primary Arm: Subjects with AIAA/CIAA pathology, including a subset newly eligible for treatment with IBE Plus.
* Secondary Arm: Subjects requiring EVAR revision for previously treated AIAA/CIAA.
Participants will:
* Undergo pre-procedure assessments (informed consent, physical exam, lab tests, and CTA imaging).
* Receive endovascular treatment with the IBE Plus Stent Graft.
* Attend follow-up visits at 1, 6, 12, 24, 36, 48, and 60 months post-procedure for physical exams, lab tests, and imaging.
* Be monitored for adverse events, device performance, and need for reintervention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Primary Arm
Subjects representative of AIAA/ CIAA pathology to be treated with IBE Plus Stent Graft
GORE® EXCLUDER® IBE Plus Stent Graft
Endovascular aneurysm repair with the GORE® EXCLUDER® IBE Plus Stent Graft
Secondary Arm
Subjects representative of EVAR revision to be treated with IBE Plus Stent Graft
GORE® EXCLUDER® IBE Plus Stent Graft
Endovascular aneurysm repair with the GORE® EXCLUDER® IBE Plus Stent Graft
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GORE® EXCLUDER® IBE Plus Stent Graft
Endovascular aneurysm repair with the GORE® EXCLUDER® IBE Plus Stent Graft
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The target lesion and surrounding vasculature are amenable to treatment with IBE Plus system requirements:
1.1. Common iliac artery to be treated must have a common iliac diameter ≥ 25 mm with or without concomitant abdominal aortic aneurysm 1.2. Minimum diameter ≥ 12 mm within the proximal implantation zone of IBE Plus as assessed by flow lumen; calcium excluded 1.3. Intended treatment length must be ≥ 100 mm in unilateral application or a combination of ≥ 100 mm and ≥ 150 mm in bilateral application 1.4. The planned distal target landing zone within the internal iliac artery is within the trunk of the internal iliac artery with at least 15 mm of seal zone 1.5. Iliac vasculature meets anatomical specifications for selected VBX Stent Graft(s)
2. Aortoiliac vasculature meets anatomical specifications for selected EXC or EXCC Devices
3. Informed Consent Form (ICF) is signed by subject
4. Subject is capable of complying with protocol requirements, including follow-up
5. Life expectancy \> 2 years
6. Age ≥ 22 years at time of informed consent signature
7. Male or infertile female
The subject is / has:
1. Present with any one of the following treatment indications:
1.1. The subject has a confirmed Type Ib endoleak of a previously implanted Gore EVAR device where its distal portion within the common iliac artery has a luminal diameter of at least 12 mm. Minimum diameter of ≥ 12 mm within the proximal implantation zone of IBE Plus as assessed by flow lumen; calcium excluded 1.2. The subject has documented diameter growth of the common iliac artery of at least ≥ 5 mm in the presence of a previously implanted Gore EVAR device where its distal portion within the common iliac artery has a luminal diameter of at least 12 mm. The planned distal target landing zone within the internal iliac artery is within the trunk of the internal iliac artery with at least 15 mm of seal zone
2. Aortoiliac vasculature meets anatomical specifications for selected EXC or EXCC Devices
3. Informed Consent Form (ICF) is signed by subject
4. Subject is capable of complying with protocol requirements, including follow-up
5. Life expectancy \> 2 years
6. Age ≥ 22 years at time of informed consent signature
7. Male or infertile female
Exclusion Criteria
1. Mycotic or ruptured aneurysm
2. ASA class V (moribund patient not expected to live 24 hours with or without operation)
3. Renal insufficiency defined as creatinine \> 1.8 mg/dL or undergoing dialysis
4. NYHA class IV
5. Dissected, heavily calcified, or heavily thrombosed landing zone(s)
6. Tortuous or stenotic iliac and/or femoral arteries preventing introducer sheath insertion and the inability to use a conduit for vascular access
7. Participating in another investigational drug or medical device study within one year of study enrollment
8. An active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication) that may place the patient at increased risk of endovascular infection. Subjects with a chronic infection (such as HIV, Hepatitis C, etc.) that is well controlled under their current treatment regimen may be eligible
9. Degenerative connective tissue disease, e.g., Marfan's or Ehler-Danlos Syndrome
10. Planned concomitant surgical procedure or major surgery within 30 days of treatment date
11. History of drug abuse, e.g., cocaine or amphetamine, within 1 year of treatment
12. Known sensitivities or allergies to the device materials
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
W.L.Gore & Associates
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IBE 25-05
Identifier Type: -
Identifier Source: org_study_id